胰高血糖素样肽-1受体激动剂：一种用于暴饮暴食（暴饮暴食症和神经性贪食症）的新型药物疗法？一项系统评价。
GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review.
作者信息
Aoun Laurence, Almardini Shaza, Saliba Fares, Haddadin Fadi, Mourad Omar, Jdaidani Jennifer, Morcos Zeina, Al Saidi Ibrahim, Bou Sanayeh Elie, Saliba Saliba, Almardini Michel, Zaidan Julie
机构信息
Department of Internal Medicine, Staten Island University Hospital, United States.
Department of Physiology, Mcgill University, United States.
出版信息
J Clin Transl Endocrinol. 2024 Feb 29;35:100333. doi: 10.1016/j.jcte.2024.100333. eCollection 2024 Mar.
OBJECTIVE
Systematically review evidence on using GLP-1RAs for reducing BEB in BED and BN.
METHODS
Comprehensive literature search (PubMed and Google Scholar) conducted for studies evaluating GLP-1Ras for BEB. Extracted data on study characteristics, efficacy, and safety.
RESULTS
Studies show that GLP-1RAs (liraglutide and dulaglutide) reduce BE frequency and comorbidities in addition to favorable psychiatric side effect profile compared to current options. However, large-scale, blinded placebo-controlled trials are lacking.
CONCLUSION
Early findings suggest promising effects of GLP-1RAs on BEB. However, rigorous clinical trials are needed to firmly establish efficacy, dosing, safety, and comparative effectiveness before considering GLP-1RAs a viable novel approach.
目的
系统回顾关于使用胰高血糖素样肽-1受体激动剂（GLP-1RAs）降低暴饮暴食症（BED）和神经性贪食症（BN）中暴饮暴食行为（BEB）的证据。
方法
对评估GLP-1RAs治疗BEB的研究进行全面的文献检索（PubMed和谷歌学术）。提取有关研究特征、疗效和安全性的数据。
结果
研究表明，与现有治疗方法相比，GLP-1RAs（利拉鲁肽和度拉糖肽）除了具有良好的精神科副作用外，还能降低BE频率和合并症。然而，缺乏大规模、双盲、安慰剂对照试验。
结论
早期研究结果表明GLP-1RAs对BEB有显著效果。然而，在将GLP-1RAs视为一种可行的新方法之前，需要进行严格的临床试验，以确定其疗效、剂量、安全性和相对有效性。
Zotero 插件